Boira MA, Di Martino M, Gordillo C, et al. - In this retrospective study, researchers examined the link between Glucose transporter type 1 (GLUT-1) expression and prognosis in patients suffering from pancreatic ductal adenocarcinoma (PDAC) submitted for surgical resection in a European cohort. This analysis involved 39 patients, with 58.9% presented with weak and 41.1% with strong intensity. Findings indicated that GLUT-1 could be associated with higher aggressivity in PDAC. Experts suggested its likely utility as a prognostic marker, detecting cases with a worse response to current treatments who could benefit from more aggressive treatments.